In summary, in the present study, we found that elevated CSF AT III levels in patients with CNS involvement of lymphoma reflect the magnitude of blood–brain barrier disruption and AT III is not an independent biomarker of lymphoma CNS involvement. The gene discussed is SERPINC1; the disease is lymphoma.